Small molecule inhibitors like anlotinib, apatinib, and lenvatinib, as well as monoclonal antibodies like bevacizumab are anti-angiogenic agents that reduce tumor angiogenesis by disrupting the VEGF signaling pathway, resulting in anti-tumor effects. Here, VEGFA is linked to neoplasm.